NCT05551507View on ClinicalTrials.gov

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Platinum-resistant Ovarian Cancer
Interventions
DRUG

IN10018 in combination with PLD

IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer

Trial Locations (7)

Unknown

RECRUITING

Anyang Cancer Hospital, Anyang

RECRUITING

Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Affiliated Obstetrics and Gynecology Hospital of Zhejiang University, Hangzhou

RECRUITING

Tianjin Cancer Hospital, Tianjin

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY